Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 8, 2009

GE Healthcare to Provide Cytori’s Adipose-Derived Stem Cell Technology in North America

  • GE Healthcare agreed to commercialize Cytori Therapeutics’ StemSource® technology in the North American stem cell banking and research markets. The partnership will extend for 18 months starting in the second quarter of 2009.

    StemSource includes automated equipment to process stem and regenerative cells found in adipose tissue, cryopreserve them, or use them directly for research purposes.

    In January 2009, Cytori and GE Healthcare formed a separate agreement to commercialize Cytori’s products in 10 European countries. This includes selling the Celution® 800/CRS System in the European cosmetic and reconstructive surgery market as well as selling

    StemSource products in the European cell banking and research markets.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »